|
|
|
|
| It’s impossible to attend an event on the future of RNA therapeutics without hearing about the challenges we’re facing with targeted RNA-LNP delivery. In this final Advancing RNA Live discussion of 2024, we sit down with three LNP experts to parse out the current opportunities and unknowns facing the development of next-generation LNPs. Secure your spot today! Registration is free thanks to the support of Helix Biotech. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | Fortunately for us, a recent panel shared a few important reminders as we navigate mRNA in a variety of different therapeutic applications and, perhaps, as we explore the implementation of advanced manufacturing technologies in our mRNA-LNP manufacturing processes. In the second of this three-part article series, I walk through one big takeaway I had from a recent conversation about the current state of mRNA regulatory affairs. |
|
|
|
By Craig Tooman, president and CEO, Silence Therapeutics | Silence Therapeutics has two wholly owned siRNA therapies now in clinical trials and one partnered program with AstraZeneca. Silence's CEO discusses the need for good science, making smart business decisions, and cultivating partnerships. |
|
|
|
By Ioanna Deni, BioPlan Associates Inc. | BioPlan Associates 21st Annual Report found biopharma companies want lower cost single-use system options over any other new product development area. |
|
|
|
|
|
| A New Centre For Continuous mRNA Manufacturing | Article | ReciBioPharm | Explore how a partnership between academia, regulatory agencies, and manufacturing organizations has the potential to reshape the way we produce and distribute mRNA-based therapies. |
|
|
| Demand More From Your Oligo Synthesizer | Article | Cytiva | The market for oligonucleotide therapeutics is expanding, and the pipeline is diverse. Gain insight into how you can fast-track your molecule's development with scientific support and expertise. |
|
|
.png){kind=logo}
